NotAIDS! Editorial
November 6, 2007

HIV care kills. With careful planning, career AIDS researchers can take advantage of these deaths to enhance their publishing cachet.

Many research studies use death as the endpoint. It seems too bizarre to be true, but it is true.

It could be a vaccine trial in Africa that infects people with a synthetic, engineered DNA virus meant to resemble the collection of proteins they call HIV.

Perhaps it's a burning gel microbicide meant for African women's vaginas, or maybe they want to chop off African men's foreskin, in decidedly unsantiary conditions to see what infection he can catch now that he doesn't have the extra protection nature provided.

The industry favorite is the "international head-to-head trial, a comparison of one antiretroviral to another, across the seas. It's like the The lab cats in their white, play doctor with gay North American or European men, to see which drug kills better, faster.

Homosexuals from both continents stand by eagerly awaiting their turn in the chamber to play "Let's rot from the inside!" and "My Atripla killed my pancreas," or the end-game, "Whoever dies first, wins." The prize? They get to take their Sustiva on board the Afterlife Express.

Are there gay bars in Hell? My mother told me that's where we're all going, that must be the rush to play the deadly games.

Killing with HIV treatments has become a pastime of academic professionals and professional lab cats employed by University at taxpayer expense, funded big time by pharmaceutical companies. The higher the pay, the more fun the killing, and the more recognition by the peers.

The game is The Lab Cat Chases the Rat. Lab rats usually are gay men or black African American women, or in New York, they prefer to catch their babies and trap them at a place called Incarnation House.

Buried in the piles of AIDS "treatment" research game reports is a September 2006 paper whose authors described how they patiently chased gay Canadians in British Columbia to "find evidence that reduced sensitivity to antiretrovirals leads to rapid disease progression or death."¹

Through the administration of either "two nucleoside reverse transcriptase inhibitors and a protease inhibitor, or two nucleoside and one non-nucleoside reverse transcriptase inhibitor (NNRTI),"the researchers waited for the subjects to die."

Nearly a fifth of the study participants died during the follow-up period. Most of these patients actually had drug-sensitive viruses, possibly because they had neglected taking their drugs to such an extent that there had been insufficient drug exposure to select for drug-resistant viruses.

In a quarter of the patients, however, HIV strains resistant to one or more antiretroviral drugs emerged during the study (again judged by looking for mutations).

Detailed statistical analyses indicated that the emergence of any drug resistance nearly doubled the risk of patients dying, and that people carrying viruses resistant to NNRTIs were three times as likely to die as those without resistance to this class of antiretroviral drug.

Put another way, the body's natural systems, like DNA transcription, RNA reverse transcription, or protease production, evade pharmaceutical toxins as long as they can until the collateral damage becomes fatal.

In even more clear terms, the antiretrovirals don't work - that's what is meant by resistance. They don't improve quality of life; the opposite is true: they damage internal organs. If the HIV doesn't have "mutations" with "resistance" then it's the subjects' fault. They should have done better, and taken more pills, sooner.

Once they do take the pills, if they fail, and do develop "resistance" - the object of the study, this is also attributed to the subjects, because they should have adhered more closely to the regimen, and not developed "resistant" strains.

Alas, the logic of the AIDS industry is sadistic and masochistic. Once inducted into the treatment cabal, there is no pleasing the lab cats or their masters, their funders, the pharmaceutical companies. They make eager victims from frightened and suggestible target markets, destined for death in their clinical studies,

Outside the walls of this AIDS industry of horrors, thousands upon thousands of HIV positive individuals who never took an antiretroviral quietly live normal, healthy lives, and "resistance," or "adherence," is never our issue. There is no such thing as "immune reconsitituion syndrome" or "treatment failure." We just go on living, unstudied, and unbothered, except for the silliness we read in the news.

Almost two years ago when this author's CBC blood tests came in, all results were normal, HIV having had no impact. The doctor nearly chased me down the hallway as I was about to leave. "Wait, we can do things!" he helpfully offered.

"What things?" I asked. "I'm all set, thanks," I judiciously declined his offer.

Today I go about my business healthy and do normal things like work. I have actually seen health improvements since the grand seroconversion.

Since I was a toddler (thanks, Mom!) cold sores caused me misery every couple of months with an outbreak.

I haven't had a single outbreak since becoming HIV positive about two years ago.

##

1. Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART
   Robert S Hogg,1,2,3* David R Bangsberg,4 Viviane D Lima,1 Chris Alexander,1 Simon Bonner,1 Benita Yip,1 Evan Wood,1 Winnie W. Y Dong,1 Julio S. G Montaner,1,2 and P. Richard Harrigan1,5
   1British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada
   2Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
   3Department of Health Care and Epidemiology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
   4Epidemiology and Prevention Interventions Center, Division of Infectious Diseases and the Positive Health Program, San Francisco General Hospital, San Francisco, California, United States of America
   5Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
   H. Clifford Lane, Academic Editor
   National Institutes of Health, United States of America
   * To whom correspondence should be addressed. E-mail: bobhogg@cfenet.ubc.ca
   Received January 14, 2005; Accepted June 14, 2006.
   Technorati Tags: HAART HIV death AIDS
   Forward this page to a friend

   Your Email: *

   Your Name: *

   Send To: *

   Enter multiple addresses by separateing them with commas.

   Message Subject: (Your Name) has sent you a message from NotAIDS!

   Message Body: (Your Name) thought you would like to see the NotAIDS! web site.

   Your Personal Message: *